Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer: Current status and future perspectives

touchEXPERT OPINIONS for touchONCOLOGY

Listen to three experts provide their insights on unmet needs, emerging therapies, and the importance of biomarker testing in HER2-negative gastric cancer/gastroesophageal junction cancer.

The experts:

• Dr Reetu Mukherji, MedStar Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA
• Dr Jaffer Ajani, Houston, TX, USA
• Dr Nataliya Uboha, University of Wisconsin, Madison, WI, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/exp_opin_HER2_negative_gastric_or_GE_junction_cancer